$ORIC President & CEO, @JacobChackoMD and CFO @Dom_Piscitelli will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, at 11:40 a.m. ET.
Listen to the live or archived discussion here: https://t.co/H3UikED2Ii
This #AANHPIHeritageMonth, we celebrate “Power in Unity: Strengthening Communities Together” and the profound contributions #AANHPI communities have made to science and medicine.
Diverse perspectives drive stronger innovation and better outcomes for patients.
#PowerInUnity
Q1 2026 marked continued momentum for ORIC, highlighted by rinzimetostat data supporting a potential best-in-disease profile and the selection of the RP3D for our first Phase 3 trial in mCRPC, Himalayas-1.
Explore our latest progress and what’s next here:https://t.co/qPj6fk5G7I
ORIC® VP, Head of Biology Melissa Junttila, Ph.D., & Dir., Head of Bioinformatics Alex Pankov, Ph.D., will present posters at #AACR2026 highlighting preclinical data demonstrating rinzimetostat’s potential as a differentiated treatment for prostate cancer.
Cancer Control Month reminds us that progress takes more than awareness, it takes innovation and action.
We’re working to Overcome Resistance In Cancer by developing therapies designed to address what allows disease to persist.
#CancerControlMonth
Phase 1b data for rinzimetostat + darolutamide in mCRPC highlight potential best-in-disease profile, supporting advancement into Phase 3. Join our webcast at 4:30 p.m. ET today for a detailed review & program update: https://t.co/H3UikED2Ii
Press release:https://t.co/GAXinkrXPj
We are pleased to share that two preclinical abstracts reinforcing the best-in-class potential of rinzimetostat (ORIC-944) to treat prostate cancer have been accepted for poster presentation at #AACR2026 taking place April 17-22, 2026.
Learn more here: https://t.co/z3bj4FpO8m
Happy #EmployeeAppreciationDay to our incredible team!
From team activities to recognition and wellness initiatives, we’re celebrating the people who power our mission to Overcome Resistance In Cancer every day.
Thank you for all you do.
This #InternationalWomensDay, we honor the women powering our mission to Overcome Resistance In Cancer.
Aligned with #GiveToGain, we know that when we invest in women, we strengthen science and outcomes for patients. When women thrive, we all rise.
#WomenInBiotech#IWD2026
2025 was a year of meaningful progress across our clinical pipeline.
We advanced 2 clinical programs with data highlighting differentiated efficacy & safety, building momentum toward potential registrational studies and key milestones ahead.
https://t.co/F9x7t2q76W
$ORIC CFO @Dom_Piscitelli & CBO @mattpanuwat will participate in a fireside chat at @Oppenheimer’s 36th Annual Healthcare Life Sciences conference on Wed, Feb 25, 2026, at 12:00 p.m. ET.
Listen to the discussion to learn the latest company updates here: https://t.co/H3UikECuSK
Prevention, early detection, and research all play a critical role in the fight against cancer.
This #CancerPreventionMonth, we’re reminded that progress begins long before diagnosis and continues through science.
#EarlyDetection#ScienceMatters
Welcoming the Lunar New Year and the Year of the Fire Horse, a period of high energy, rapid progress, and passionate, independent action.
Wishing our global community a year of health, renewal, and continued progress through science.
#LunarNewYear#YearOfTheFireHorse
$ORIC President & CEO, @JacobChackoMD and CFO @Dom_Piscitelli will participate in a fireside chat at @Citi’s 2026 Virtual Oncology Leadership Summit on Wednesday, February 18, 2026, at 2:30 p.m. ET.
Listen to the live or archived discussion here: https://t.co/H3UikECuSK
Today we celebrate the women and girls driving scientific discovery forward.
Advocating for equity and opportunity in STEM strengthens and accelerates innovation for patients everywhere.
#WomenInScience#GirlsInSTEM#IDWGS
$ORIC CFO @Dom_Piscitelli & CBO @mattpanuwat will participate in a fireside chat at @Guggenheim’s Emerging Outlook: Biotech Summit on Thurs, Feb 12, 2026, at 10:30 a.m. ET.
Listen to the discussion to learn the latest company updates here: https://t.co/H3UikED2Ii
Behind every cancer diagnosis is a unique human story.
This #WorldCancerDay, we stand #UnitedByUnique, advocating for people-centered cancer care that combines scientific innovation with compassion and empathy for every patient.
This #MLKDay, we honor Dr. King’s legacy & call for equity & opportunity. Diversity of thought & experience strengthens science & fuels innovation. At ORIC®, inclusion & respect are core values. We’re committed to fostering an environment where everyone feels welcome & respected.
We ended 2025 with strong momentum, reporting compelling data across rinzimetostat (ORIC-944) and enozertinib programs. As we approach 2 potential registrational studies & meaningful data milestones, we’re excited for the progress and possibilities ahead.
https://t.co/FxQwfGuys6